and gender, including physician visits, pain-clinic visits, neurology-clinic visits, and ED visits. In the 75–84 years age group, frequency of utilization was higher by 22%, 39%, 45% and 48% for these health care resources, respectively.

CONCLUSIONS: Epidemiology of HZ in Israel is similar to that reported for other countries. This illness presents a burden on the elderly population and is related with increased resource utilization.

P197

COST BENEFIT ANALYSIS ON THE LONG TERM EFFECTS OF IN VITRO FERTILIZATION (IVF) IN GREECE: AN ANALYSIS BASED ON A LIFETIME MODEL

Fragoulakis V, Maniadakis N

National School of Public Health, Athens, Greece

OBJECTIVES: To quantify the economic effects of an in-vitro-fertilization (IVF) born persons in terms of productivity gains and net tax revenues for the state in Greece.

METHODS: A mathematical model was developed to assess the lifetime productivity and transactions between an individual and the governmental agencies. The model was divided in three life period: 1) child-rearing, when the government primarily contributes resources through child tax credits, health care, and educational expenses; 2) employment, when individuals begin returning resources through taxes; and 3) retirement, when the government expects additional resources on Social Security and old-age programs. Cost of life birth with IVF was based on a modification of a previous published model developed by the authors. All outcomes were discounted at a 3% discounting rate. The data inputs, namely the economic or demographic variables, were derived from National Center for Health Statistics Total Fertility Rate in Greece and other relevant sources. To deal with uncertainty, bias corrected uncertainty intervals (UI) was calculated based on 5000 Monte Carlo simulations. In addition, to examine the robustness of our results, other one-way sensitivity analyses were also employed. RESULTS: The cost of IVF per birth was estimated at €17,078 (95% UI: €16,350–€17,805). The average projected income per individual throughout the period is €67,651 (95% UI: €53,897–€76,822). In addition, his life tax contribution was estimated at €200,295 (95% UI: €168,669–€228,670), while the discounted governmental expenses for elderly and underaged individuals were at €36,570 (95% UI: €33,614–€40,463). Hence, the net present value of IVF was €776,124 (95% UI: €64,419–€214,215) representing a 54% net return on investment. Results remained constant under various assumptions for the main model parameters. CONCLUSIONS: State-funded IVF represents good value for money in the Greek setting, as it has positive tax benefits for the government, notwithstanding its beneficial psychological effect for infertility couples and the overall productivity gains.

P181

CLINICAL EFFICACY AND COST-EFFECTIVENESS OF ADDITIONAL IMMUNOTHERAPY IN EARLY-ONSET NEONATAL INFECTIONS

Soldatova I1, Pankratyeva L2, Degtyareva M2, Volodin N3

1Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia, 2Russian National Research Medical University, Moscow, Russia, 3Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

OBJECTIVES: To compare the clinical effects of a standard Total Parenteral Nutrition (TPN) regimen with the clinical effects of a TPN enhanced with Omega-3 fatty acids in neonates with severe infections in neonatal intensive care unit (NICU).

METHODS: We observed 375 neonates (gestational age (GA) 24-41 weeks) with severe early-onset infections in NICU. Fifty-two neonates with hyperammonemia were treated with normal human immunoglobulin (NHI) and hyperammonemia with lypoliposomes treated with human immunoglobulin (HI2, 2b), 94 neonates with low mitogen-induced interferon-alfa production treated with interferon-alfa 2b. A total of 144 were under standard treatment without additional immunotherapy. RESULTS: Administration of NHI resulted in reduction of NICU length of stay and mortality rates from severe infection (p<0.009, OR 0.21 [0.05; 0.67], RR 0.26 [0.07; 0.69], NNT=8 [4; 29]). Administration of HI2 reduces NICU length of stay and mortality rates from severe infection (p<0.009, OR 0.36 [0.13; 0.98], RR=0.41 [0.17; 0.98], NNT=9 [4; 214]). Administration of immunotherapy in early-onset neonatal infections leads to substantial cost savings up to €168,896 per patient in case of NICU treatment, €60,910 per patient in case of HI2 treatment and €168,669-228,670, per patient in case of HI2b administration.

CONCLUSIONS: Additional immunotherapy in early-onset neonatal infections is a cost-effective intervention that allows to reduce mortality rates and save money.

P198

COST EFFECTIVENESS OF SUPPLEMENTAL N-3 IN TOTAL PARENTERAL NUTRITION (TPN) FOR THE TREATMENT OF PREGNANCY-INDUCED DIABETES MELLITUS (PDM)

PIH18

PIH20

COST EFFECTIVENESS OF PREMALEX (ESCITALOPRAM) COMPARED TO SARC (LEVONORGESTREL INTRACUTANEOUS SYSTEM) IN THE TREATMENT OF PREMENSTRUAL DISCOMFORT (PMDD) FROM A THIRD-PARTY PAYER PERSPECTIVE

Pradelli L1, Endzi M2, Povero M2, Meyer K2, Heller AR3, Mucarselotti M4

Ades Rea & Or, Turin, Italy. 2University of Turino, Torina, Italy, 3Justus-Liebig University Giessen, Giessen, Germany, 4Universitätsklinikum Carl Gustav Carus at the Technical University Dresden, Dresden, Germany

OBJECTIVES: A very recent Meta-Analysis shows that the addition of Omega-3 fatty acids to standard Total Parenteral Nutrition (TPN) is associated with reductions in infection rate, ICU, and overall length of stay (LOS) for both Intensive Care Unit (ICU) and elective surgery patients. Aim of this study is the CE analysis of its use in these patient populations, as compared to standard lipid emulsions.

METHODS: Within a Discrete Event Simulation (DES) scheme, a patient-level simulation model was developed, with the inclusion of baseline outcomes rates from the Italian ICU patient population and from published literature, comparative efficacy data for standard and Omega-3 fatty acids-based regimens from the meta-analysis of published randomized clinical trials (conducted on 23 studies with a total of 1502 participants). Sensitivity analyses included in the model are death rates, nosocomial infection rates, and ICU/hospital LOSs. Costs are referred to Italian, French German and UK health care systems. Probabilistic and deterministic sensitivity analyses are undertaken to test results’ reliability.

RESULTS: Additional n-3 emulsions emerged as more effective on average than the standard TPN both in ICU and in non-ICU patients: in all the four national contexts here considered, reduced mortality rates, infection rates, and overall LOSs yield a lower total cost per patient. Treatment costs are completely offset by the reduction in hospital costs and antibiotic costs. Sensitivity analyses confirmed the robustness of these findings. CONCLUSIONS: These results indicate that the addition of Omega-3 to standard TPN is expected to improve clinical outcomes and consequently give a saving for Italian, French, German and UK hospitals.

P191

HEALTH ECONOMIC EVIDENCE IN SUPPORT OF A LOW-DOSE CONTRACEPTIVE LEVONORGESTREL INTRACUTANEOUS SYSTEM (LNG-IUS 12) COMPARED TO SARC (LEVONORGESTREL INTRAUTERINE SYSTEM) FROM A THIRD-PARTY PAYER PERSPECTIVE

Trussell J1, Hassan F2, Hendy N3, Law A4, Fucoki S5, Filonenko A6

1Princeton University, Princeton, NJ, USA, 2JMS Health, London, UK, 3Bayer Healthcare Pharmaceuticals, Inc., Wayne, NJ, USA, 4Bayer Pharma AG, Berlin, Germany

OBJECTIVES: LNG-IUS 12 is a less expensive and more effective contraceptive system for up to 3 years use with an average in vitro release rate of 12ug of levonorgestrel per day. This study was conducted to estimate the relative cost-effectiveness of LNG-IUS 12 versus short-acting reversible contraception (SARC) in the United States from a third-party payer’s perspective. METHODS: A Markov model was constructed to compare the effectiveness and costs of LNG-IUS 12 and SARC over a 5-year period in a cohort of 1000 women aged 20 to 29 years, the age group in which most unplanned pregnancies occur. SARC methods comprise contraceptives commonly used by this age cohort, including oral contraceptives, the ring, the patch and injections. Primary health states included initial/continued use of contraceptive and number of unplanned pregnancies associated with SARC. Sensitivity analyses confirmed the robustness of these findings. CONCLUSIONS: These results indicate that the addition of Omega-3 to standard TPN is expected to improve clinical outcomes and consequently give a saving for Italian, French, German and UK hospitals.

P192

CLINICAL EFFICACY AND COST-EFFECTIVENESS OF HUMAN RECOMBINANT INTERFERON-α2B IN NEONATAL INFECTIONS

Soldatova I1, Pankratyeva L2

1Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia, 2Russian National Research Medical University, Moscow, Russia

OBJECTIVES: To investigate the cost effectiveness of intermittent treatment of PMDD (premenstrual dysphoric disorder) with Premalex (escitalopram) 20 mg compared with the treatment of 40 mg based on the Clinical Global Impressions – Severity (CGI-S), from a societal perspective. METHODS: We identified one randomised placebo controlled trial with sertraline and one with Premalex, reporting the CGI-S as an outcome. Using placebo, the CGI-S was used to make an indirect effect comparison between Premalex and sertraline. The CGI-S was translated into QALY weights, through the proportion of time spent with a high degree of depression/depression in the EQ-SD. Costs of health care visits were estimated using a local treatment pattern survey among GPs and gynaecologists. Official drug costs were used. A Premalex dose of 15 mg, the average of 10 and 20 mg, was assumed as it is stated in the SPC text that the majority of the patients will benefit from 10 mg. 37–75% lower drug costs were used in years 2-3 due to expected generic competition. Indirect costs were estimated using a published international study of the effect of PMDD on sick leave and productivity. A societal perspective was taken over a 3-year time horizon.

RESULTS: During the first year, Premalex treated infants added increased drug costs (SEK 1599), partly offset by indirect costs saving (SEK 1413), resulting in a total cost of SEK 186, compared to sertraline. An estimated gain of 0.004 QALYs with Premalex compared to sertraline gave an incremental cost per QALY gained of SEK 42200 (EUR 4772) per patient over 2 years, drug costs being more than offset by indirect costs saving, leading to an overall gain of 0.0132 QALYs and a savings of SEK 1600 per three years with Premalex compared to sertraline. CONCLUSIONS: Treatment of PMDD with Premalex is cost effective compared to sertraline, from a societal perspective.